IL-32 is onae of the last important cytokines discovered, produced mainly by T cells, natural killer cells, and epithelial cells. Probably many other different cells are a source oflL-32, which has been found to be a powerful pro-inflammatory mediator. Here we studied the effect of IL-32 on histamine release by human-derived cord-blood mast cells. In these studies we found that IL-32 significantly stimulates the release of histamine only at high concentrations (100 ng/ml) while at 10 or 50 ng/ml it had no effect. These results were found for the first time and demonstrate that IL-32 may play an important role in allergic and inflammatory diseases.
Although several types of cells have been proposed to trigger inflammation, the etyologic process and pathogenesis of the disease remains controversial (27) (28) .
Recent studies indicate that the mast cell is emerging as a key player in inflammatory events leading to tissue destruction (29) (30) (31) (32) (33) . In addition, increasing evidence indicates that mast cells are involved in. the pathophysiology of inflammatory diseases and in allergic and anaphylactic reactions (34) (35) . The aim of this study is to investigate the role of IL-32 in stimulating histamine release from HCBMC, which is a good and valid model to study human mast cells.
MATERIALS AND METHODS

Human cord blood mast cell isolation, culture and treatment
Umbilical cord blood was collected in tubes containing 10 U/ml heparin and diluted 1:2 with Dulbecco's phosphate buffered saline (DPBS) from GIBCO BRL (Life Technologies, Grand Island, NY) containing 2 mM ethylenediamine-tetra acetic acid (Sigma). Nonphagocytic mononuclear cells were separated by densitygradient centrifugation using Lymphocyte Separation Medium (LSM) from Organon Teknika Corp (Durham, NC). The isolation of hematopoietic stem cells (CD34+) was performed by positive selection of CD34+/ACI33+ cells by magnetic associated cell sorting (MACS) using an AC133+ cell isolation kit (Milltenyi Biotec, Auburn, CA). CD133 expression is restricted to a subset ofCD34 bright positive stem cells in human cord blood. Mast cells had been obtained by culturing cord blood mononuclear cells in the presence of SCF, IL-6. CD34+ cells were suspended in Iscove's Modified Dulbecco's Medium (IMDM; GIBCO BRL), supplemented with 100 ng/ml rhSCF, 50 ng/ml IL-6, 10% fetal bovine serum (FBS; Bio whittaker, Walkesville, MD), 5x 10-5 M2-Mercaptoethanol, and I% penicillin-streptomycin (GIBCO BRL) for 12 to 16 weeks. During this culture period, the cells were washed with DPBS every week and resuspended using fresh complete culture medium. Mast cell viability was determined by trypan blue (0.3%) exclusion and observed under light and electron microscope ( Fig. I) .
For sensitization, hCBMCs were washed with DPBS and plain culture medium (without any growth factors) once in each and resuspended in serum-free complete culture medium, but without IL-6 supplementation. Cells (lx10 6 cells/ml) were then incubated with human myeloma-IgE (2 ocg/ml) at 37°C for 48 h in 24-well Falcon cell culture plates (Becton Dickinson, Franklin Lakes, NJ). These sensitized HDCBMCs were used in all the experiments.
Activation ofhCBMC with ANTI-IgE
Anti-Human IgE (DAKO Rabbit anti-Human IgE, Specific for Epsilon-chains. Code number A 0094; Lot no. 069. Edition 05.07.00) was used in this study at different concentrations: 1, 5 and 10 ug/rnl, For anti-IgE stimulation experiments, hCBMC (10 6 cells/ml) were washed with Iscove's modified Dulbecco's medium and Tyrode's buffer, once in each, and passively sensitized by incubation with human myeloma IgE (2 ug/ml/I 0 6 cells; Chemicon Inc.) for 48 h in culture medium at 37°C. Cells were then washed two times and resuspended in fresh culture medium. Cells were stimulated with anti-IgE (Dako) at 15 ug/ml in 96-well round bottom culture plates (2 x IO' cells in 200 III medium! sample) for 6 h at 37°C in 5% CO 2 . Tryptase was measured in the supernatants and cell pellets by fluoroenzyme-immunoassay (Pharmacia, Uppsala, Sweden). CRH, Ucn, and tryptase results were expressed as pg/ml and as percent of total = (supernatant! (supernatant + pellet) x 100%. This presentation allowed normalization of any baseline differences between cultures. These peptides were measured in the supernatant and pellet to calculate percent release.
IL-32 was purchased by R&D Minneapolis MN, USA.
Histamine measurement
Histamine in cells or histamine released to growth medium was estimated by a radioenzymatic method. HDCBMC were washed, trypsinized and harvested by centrifugation at 400 x g for 5 min in 1.5 ml Eppendorf tubes. Cells were then resuspended in water (5 x 10 6/0.2 ml). This suspension was sonicated in Branson 1200 ultrasound device for 10 min, vortexed for 5 min and pelleted by 10 min centrifugation at top speed in an Eppendorfmicrocentrifuge. Histamine in growth medium taken from growing cells or from cells treated with 19E and antigen was estimated after pelleting the cells by centrifugation at 400 x g for 5 min. To 20 gl of supernatant taken from disrupted cells or to 20 III of growth media 2 III 20% perchloric acid, 6 III I N NaOH and 100 III 0.05 M sodium phosphate pH 7.4 was added. The precipitate was pelleted by 5 min centrifugation at top speed in an Eppendorf microfuge and aliquots were taken from the supernatant for further histamine assay. In 50 gl of reaction mixture for histamine assay 5-25 III sample, 5 III rat kidney histamine methyl transferase and S-(methyl-3H) adenosyl-L methionine (73.8 Ci/mM, Amersham) were present. Isotope and enzyme were diluted with 0.05 M sodium phosphate pH 7.4 for optimal conditions. The reaction mixture was incubated I h at 37°C, following which 20 1-11 1.5 M perchloric acid, 20 1-11 10 M NaOH and 500 1-11 freshly prepared toluene-isoamylalcohol (4: I vol/vol) was added and the mixture was shaken for 10 min. After 10 min centrifugation at 200 x g, 0.3 ml was taken from the upper phase and 4 ml of Aquasol (New England Nuclear, Boston, MA) scintillation fluid was added: Radioactivity was measured in a beta counter and the concentration of histamine was computed by using a standard curve. Samples were always performed in duplicate from duplicate cultures.
Statistical Analyses
Data from 4 representative experiments performed in triplicate were combined andreported as the mean ± S.D. Student's t-test forindependent means wasused to provide statistical analyses (P\0.05 was considered significant).
RESULTS
Dose-response experiments
In order to study the full influence .of IL-32 on histamine release from HDCBMC, we used IL-32 at different concentrations 10 -15 -and 100 ng/ml (Fig. 1) . The results were that IL-32 did not stimulate histamine release at the concentration of 10 and 15 ng/ml; while used at the highest concentration 100 ng/ml, the release of histamine was significantly higher than the control. Anti-lgE used as a positive control strongly stimulated the release of histamine on HDCBMC.
Time course experiments
In these studies we used IL-32 at different times of incubation: 1-2-3 minutes on HDCBMC (Table I) . We found that the maximum stimulation ofhistamine by IL-32 (100 ng/ml) occurred at 2 and 3 minutes of incubation, however, at I minute the stimulation of IL-32 was not significant compared to the control.
DISCUSSION
Mast cell producing cytokines/chemokines can substantially enhance T cell recruitment to local infection demonstrating that they are not only important in IgE-associatcd disorders, but also contribute to the host defence against bacteria (36) (37) (38) (39) (40) (41) . Mast cells have diverse potential contribution during innate and acquired immunity and in other biological responses (42) (43) (44) (45) . These findings suggest that mast cells may have a much more versatile role than previously suspected.
In this study we show for the first time that IL-32 significantly increases histamine release in HCBDMC, however, this increase was found only at very high concentrations (lL-32 at 100 ng/ml).
The response of mast cells to non-IgE-mediated stimulation is critically dependent on the population of mast cells examined. IL-32 has been reported to activate inflammatory cells (46) (47) (48) (49) (50) . Responsiveness to IL-32 was monitored measuring histamine release on HDC mRNA expression. These findings indicate that IL-32 can activate human cord bloodderived mast cells, and local IL-32 production in inflammatory sites may lead to the increase in mast cell secretion of histamine and worsen inflammatory states (51) (52) (53) (54) .
The fact that IL-32 has an important role in the inflammatory cytokine cascade led to the development of an anti-IL-32 antibody to treat inflammatory diseases such as rheumatoid arthritis and allergy. Anti-IL-32 therapy in inflammatory diseases may target IL-32. The biological consequence of the activation and degranulation of mast cells in inflammatory diseases are extremely complex, and depend on the release of various combinations of soluble and granular factors (55) (56) (57) . We have a poor understanding of the quantity and quality of the agents released by the mast cells, but the rapid release ofhistamine will almost certainly induce localized tissue edema and disruption of the stromal matrix.
IL-32 was originally termed natural killer cell transcript 4 and reported to induce TNFa, IL-8 and MIP-2 in various cell types (58) . It was initially reported that stimulated lymphocytes were the primary source ofIL-32 (59) (60) (61) . However, recently it was found that many cells produce IL-32 such as, stimulated monocytes, B cells, epithelial cells, dendritic cells, and it was reported that it also has stimulatory effects on mast cells production of histamine (61) .
An abundant IL-32 expression has been found in the synovial-infiltrated lymphocytes of rheumatoid arthritis patients. The effect of IL-32 on mast cells are believed to be mediated through specific membrane receptors, and these binding sites may be present or absent in different cells. Anti-IgE-induced release from HCBMC was rapid (within 1 min). These results suggested the potential contribution of IL-32 to allergy and inflammation mediated by human mast cells.
